TnP Peptide Suppresses Experimental Autoimmune Encephalomyelitis (EAE) in a Preclinical Mouse Model

The study investigates TnP, a synthetic peptide, for its potential in treating multiple sclerosis (MS) using a preclinical animal model called experimental autoimmune encephalomyelitis (EAE). TnP has shown promise in suppressing the disease in EAE, reducing its severity. The research compares TnP's effects to existing first-line disease-modifying therapies (DMTs) like betaseron, glatiramer, and fingolimod. It assesses how well TnP protects against clinical symptoms and controls leukocyte infiltration into the spinal cord. The study also looks at TnP's ability to induce immune tolerance and neuronal regeneration, which could have significant therapeutic benefits for MS and other autoimmune diseases.

• 1
  Prophylactic treatment with TnP offered similar protection to betaseron and better protection than glatiramer or fingolimod against the development of clinical symptoms in the EAE model.
• 2
  TnP was more effective than betaseron and fingolimod in the long-term control of neuronal degeneration in demyelinated areas of the spinal cord.
• 3
  Compared to glatiramer, TnP was more efficient in reversing leukocyte infiltration into the spinal cord and induced a higher percentage of regulatory cells in both the spleen and spinal cord.